Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
MALVERN, Pa., Nov. 09, 2017 -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced with great sorrow that Rick Bierly, a valued member of the company's board of directors and chairman of the audit committee of the board, has passed away.
“Rick was a highly appreciated board member with comprehensive medical and business experience, and we are deeply saddened by his passing. He was an inspiring leader and friend. He brought great value and warmth to our company and he will be greatly missed,” said Aclaris’ President and CEO Dr. Neal Walker.
“Rick was appointed to Aclaris Therapeutics’ board of directors on October 2015, and he made valuable contributions to the Board during his tenure. Our thoughts are with Rick’s family.”
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact:
Aclaris Contact
Michael Tung, M.D.
Investor Relations
484-329-2140
[email protected]
